Myopia - Market Insights, Epidemiology and Market Forecast-2028
This report can be delivered to the clients within 24 hours
DelveInsight’s ‘Myopia - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Myopia in the United States.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Myopia from 2017 to 2028 in the United States. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Myopia - Disease Understanding
Myopia is a scientific term for nearsightedness. It occurs when the focused image falls anterior to the retinal photoreceptor layer of the eye. There are two distinct forms of myopia. The simple, less severe form, which is also called physiologic or school myopia, occurs as a result of the correlative failure of the refractive components of the normal eye. It may also result from an increase in curvature of the surface of cornea or lens or increased axial diameter of the eye. It involves myopia up to – 6.0 D. The rare form, known as pathological, degenerative, malignant or high myopia causes progressive elongation of the globe and an accompanying stretching of the scleral wall, leading to a high refractive error of – 6 D or higher. High myopia often leads to atrophy of the choroid and subsequent retinal macular degeneration, with loss of central visual acuity and high prevalence of retinal detachment, glaucoma, and strabismus. High myopia is a major cause of legal blindness in many developed countries. Both genetic and environmental factors have been implicated in the etiology of myopia, but the precise molecular mechanism behind this condition remains to be known. Five loci for high myopia have been reported including four autosomal dominants (AD) loci on 18p11.31, 12q21-q23, 7q36 and 17q21-q22 and one X-linked recessive on Xq28. The smallest haplotyped interval for these loci is that of the MYP2 locus on 18p11. Generally, once the person becomes myopic, it tends to worsen over time. Higher levels of myopia are associated with higher risks of eye diseases like glaucoma, retinal detachment, and cataract later in life.
The DelveInsight Myopia (DS) market report gives a thorough understanding of the Myopia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Myopia in the US.
Myopia Epidemiology
The Myopia (DS) epidemiology division provides the insights about historical and current patient pool and forecasted trend for the United States. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by diagnosed prevalent population, age-specific prevalent population, severity-specific prevalent population (Severity Specific Cases of Myopia in Children, Severity Specific Cases of Myopia in adults), gender-specific prevalent population of Myopia.
The DelveInsight report also provides the epidemiology trends observed in the United States during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the prevalent population of Myopia was estimated to be 92,927 in USA in 2018.
Myopia Management
There is no cure of Myopia and even the underlying causes in not well understood. The current market is mainly focused on the glasses, contact lens and surgeries to correct the vision problems in daily activities. However, these approaches have reduced the Myopia progression slightly but not much to make a difference. Normally, the most common way to treat myopia is with corrective eyeglasses or contact lenses, which refocus light onto the retina. The use of corrective eyeglasses or contact lenses can be best suggested and identified by the medical professional depending on the need and the requirement of the patients. In younger children, a technique called retinoscopy helps the eye doctor to determine the correction required. LASIK removes tissue from the inner layer of the cornea. A laser removes a precise amount of tissue to reshape the cornea and then the flap is placed back in position to heal. The correction possible with LASIK is limited by the amount of corneal tissue that can be safely removed. The therapeutic option to reduce the progression of Myopia in highly susceptible pediatric population of the United State is dependent on the off-label use of low dose Atropine. The use of Atropine has been encouraged several folds in the United States after the Optimistic results of ATOM1 and ATOM2 studies. The launch of low dose/ micro dose formulations by 2024 may increase the Atropine use significantly in the United States.
Myopia Market Outlook
The Myopia (DMD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the United States of Myopia (DMD) was estimated to be USD 85.7 million in 2018. The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028. Besides all these treatment options, the market consists of various unmet needs includes lack of therapeutic treatment, poor understanding of the mechanism of myopia. To counter the current unmet needs of the market and to provide better treatment options for Myopia, various research studies have focused on developing therapeutic treatments for Myopia, and few small molecules with lose dose formulation of atropine, have been proposed.
Myopia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
With the continuous efforts in research and development, few companies are developing therapies, NVK-002 (Nevakar), Micropine (Eyenovia), are expected to enter the United States market by 2024.
NVK-002 is a topical eye drop formulation of atropine being developed by Nevakar for the treatment of patients with myopia. This therapeutic molecule is intended to slow the progression of myopia in children. Currently, the company is investigating this molecule in Phase III stage of development and is expected to enter the market by 2024.
Micropine is a proprietary, microdose formulation of atropine and product candidate for the prevention of progressive myopia in children. In previous phase II study, this therapeutic molecule is showing better results. Recently, the company has received clearance from FDA and planning to conduct Phase III in the first half of 2019. This therapeutic molecule is expected to enter the United States market by 2024.
Myopia Report Insights
DelveInsight’s ‘Myopia - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Myopia in the United States.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Myopia from 2017 to 2028 in the United States. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
Myopia - Disease Understanding
Myopia is a scientific term for nearsightedness. It occurs when the focused image falls anterior to the retinal photoreceptor layer of the eye. There are two distinct forms of myopia. The simple, less severe form, which is also called physiologic or school myopia, occurs as a result of the correlative failure of the refractive components of the normal eye. It may also result from an increase in curvature of the surface of cornea or lens or increased axial diameter of the eye. It involves myopia up to – 6.0 D. The rare form, known as pathological, degenerative, malignant or high myopia causes progressive elongation of the globe and an accompanying stretching of the scleral wall, leading to a high refractive error of – 6 D or higher. High myopia often leads to atrophy of the choroid and subsequent retinal macular degeneration, with loss of central visual acuity and high prevalence of retinal detachment, glaucoma, and strabismus. High myopia is a major cause of legal blindness in many developed countries. Both genetic and environmental factors have been implicated in the etiology of myopia, but the precise molecular mechanism behind this condition remains to be known. Five loci for high myopia have been reported including four autosomal dominants (AD) loci on 18p11.31, 12q21-q23, 7q36 and 17q21-q22 and one X-linked recessive on Xq28. The smallest haplotyped interval for these loci is that of the MYP2 locus on 18p11. Generally, once the person becomes myopic, it tends to worsen over time. Higher levels of myopia are associated with higher risks of eye diseases like glaucoma, retinal detachment, and cataract later in life.
The DelveInsight Myopia (DS) market report gives a thorough understanding of the Myopia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Myopia in the US.
Myopia Epidemiology
The Myopia (DS) epidemiology division provides the insights about historical and current patient pool and forecasted trend for the United States. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by diagnosed prevalent population, age-specific prevalent population, severity-specific prevalent population (Severity Specific Cases of Myopia in Children, Severity Specific Cases of Myopia in adults), gender-specific prevalent population of Myopia.
The DelveInsight report also provides the epidemiology trends observed in the United States during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the prevalent population of Myopia was estimated to be 92,927 in USA in 2018.
Myopia Management
There is no cure of Myopia and even the underlying causes in not well understood. The current market is mainly focused on the glasses, contact lens and surgeries to correct the vision problems in daily activities. However, these approaches have reduced the Myopia progression slightly but not much to make a difference. Normally, the most common way to treat myopia is with corrective eyeglasses or contact lenses, which refocus light onto the retina. The use of corrective eyeglasses or contact lenses can be best suggested and identified by the medical professional depending on the need and the requirement of the patients. In younger children, a technique called retinoscopy helps the eye doctor to determine the correction required. LASIK removes tissue from the inner layer of the cornea. A laser removes a precise amount of tissue to reshape the cornea and then the flap is placed back in position to heal. The correction possible with LASIK is limited by the amount of corneal tissue that can be safely removed. The therapeutic option to reduce the progression of Myopia in highly susceptible pediatric population of the United State is dependent on the off-label use of low dose Atropine. The use of Atropine has been encouraged several folds in the United States after the Optimistic results of ATOM1 and ATOM2 studies. The launch of low dose/ micro dose formulations by 2024 may increase the Atropine use significantly in the United States.
Myopia Market Outlook
The Myopia (DMD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the United States of Myopia (DMD) was estimated to be USD 85.7 million in 2018. The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028. Besides all these treatment options, the market consists of various unmet needs includes lack of therapeutic treatment, poor understanding of the mechanism of myopia. To counter the current unmet needs of the market and to provide better treatment options for Myopia, various research studies have focused on developing therapeutic treatments for Myopia, and few small molecules with lose dose formulation of atropine, have been proposed.
Myopia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
With the continuous efforts in research and development, few companies are developing therapies, NVK-002 (Nevakar), Micropine (Eyenovia), are expected to enter the United States market by 2024.
NVK-002 is a topical eye drop formulation of atropine being developed by Nevakar for the treatment of patients with myopia. This therapeutic molecule is intended to slow the progression of myopia in children. Currently, the company is investigating this molecule in Phase III stage of development and is expected to enter the market by 2024.
Micropine is a proprietary, microdose formulation of atropine and product candidate for the prevention of progressive myopia in children. In previous phase II study, this therapeutic molecule is showing better results. Recently, the company has received clearance from FDA and planning to conduct Phase III in the first half of 2019. This therapeutic molecule is expected to enter the United States market by 2024.
Myopia Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- United States Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Myopia market.
- Organize sales and marketing efforts by identifying the best opportunities for Myopia market.
- To understand the future market competition in the Myopia market.
1 KEY INSIGHTS
2 DISEASE OVERVIEW: MYOPIA
2.1 Introduction
2.2 Sign and Symptoms
2.3 Classification of Myopia
2.4 Causes of Myopia
2.5 Pathophysiology of Myopia
2.6 Diagnosis of Myopia
2.7 Risk and Complications
3 EPIDEMIOLOGY AND PATIENT POPULATION
3.1 Key Findings
4 UNITED STATES-EPIDEMIOLOGY OF MYOPIA
4.1 Assumptions and Rationale
4.2 Total Prevalent Cases of Myopia in the United States
4.3 Age-Specific Cases of Myopia in the United States
4.4 Gender Specific Cases of Myopia in the United States
4.5 Severity Specific Cases of Myopia (Children) in the United States
4.6 Severity Specific Cases of Myopia (Adults) in the United States
5 CURRENT TREATMENT PRACTICES
5.1 Treatment options for progressive myopia
5.2 Management Strategy for Myopia Correction
6 UNMET NEEDS
7 EMERGING THERAPIES
7.1 Key cross competition- Emerging Therapies
7.2 NVK-002: Nevakar
7.2.1 Product Description
7.2.2 Other Developmental Activities
7.2.3 Clinical Development
7.2.4 Advantages and Disadvantages
7.2.5 Product Profile
7.3 MicroPine: Eyenovia
7.3.1 Product Description
7.3.2 Other Developmental Activities
7.3.3 Advantages and Disadvantages
7.3.4 Safety and Efficacy
7.3.5 Product Profile
8 MYOPIA: UNITED STATES MARKET ANALYSIS
8.1 Key Findings
1 MARKET OUTLOOK BY COUNTRY
2 THE UNITED STATES: MARKET OUTLOOK
2.1 United States Market Size
2.1.1 Total Market size of Myopia
2.1.2 Myopia Market by Therapies
3 MARKET DRIVERS
4 MARKET BARRIERS
5 APPENDIX
5.1 Report Methodology
6 DELVEINSIGHT CAPABILITIES
7 DISCLAIMER
8 ABOUT DELVEINSIGHT
2 DISEASE OVERVIEW: MYOPIA
2.1 Introduction
2.2 Sign and Symptoms
2.3 Classification of Myopia
2.4 Causes of Myopia
2.5 Pathophysiology of Myopia
2.6 Diagnosis of Myopia
2.7 Risk and Complications
3 EPIDEMIOLOGY AND PATIENT POPULATION
3.1 Key Findings
4 UNITED STATES-EPIDEMIOLOGY OF MYOPIA
4.1 Assumptions and Rationale
4.2 Total Prevalent Cases of Myopia in the United States
4.3 Age-Specific Cases of Myopia in the United States
4.4 Gender Specific Cases of Myopia in the United States
4.5 Severity Specific Cases of Myopia (Children) in the United States
4.6 Severity Specific Cases of Myopia (Adults) in the United States
5 CURRENT TREATMENT PRACTICES
5.1 Treatment options for progressive myopia
5.2 Management Strategy for Myopia Correction
6 UNMET NEEDS
7 EMERGING THERAPIES
7.1 Key cross competition- Emerging Therapies
7.2 NVK-002: Nevakar
7.2.1 Product Description
7.2.2 Other Developmental Activities
7.2.3 Clinical Development
7.2.4 Advantages and Disadvantages
7.2.5 Product Profile
7.3 MicroPine: Eyenovia
7.3.1 Product Description
7.3.2 Other Developmental Activities
7.3.3 Advantages and Disadvantages
7.3.4 Safety and Efficacy
7.3.5 Product Profile
8 MYOPIA: UNITED STATES MARKET ANALYSIS
8.1 Key Findings
1 MARKET OUTLOOK BY COUNTRY
2 THE UNITED STATES: MARKET OUTLOOK
2.1 United States Market Size
2.1.1 Total Market size of Myopia
2.1.2 Myopia Market by Therapies
3 MARKET DRIVERS
4 MARKET BARRIERS
5 APPENDIX
5.1 Report Methodology
6 DELVEINSIGHT CAPABILITIES
7 DISCLAIMER
8 ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Classification of Myopia
Table 2: Possible Etiologies of Myopia by Classification
Table 3: Total Prevalent Cases (in thousand) of Myopia in the US (2016-2028)
Table 4: Age-Specific Cases (in thousand) of Myopia in the US (2016-2028)
Table 5: Gender Specific Cases (in thousand) of Myopia in the US (2016-2028)
Table 6: Severity Specific Cases (in thousand) of Myopia (Children) in the US (2016-2028)
Table 7: Severity Specific Cases (in thousand) of Myopia (Adults) in the US (2016-2028)
Table 8: NVK-002, Clinical Trial Description, 2018
Table 9: United States Market Size of Myopia in USD Million (2016-2028)
Table 10: United States Market Size of Myopia by Therapies in USD Million (2016-2028)
Table 1: Classification of Myopia
Table 2: Possible Etiologies of Myopia by Classification
Table 3: Total Prevalent Cases (in thousand) of Myopia in the US (2016-2028)
Table 4: Age-Specific Cases (in thousand) of Myopia in the US (2016-2028)
Table 5: Gender Specific Cases (in thousand) of Myopia in the US (2016-2028)
Table 6: Severity Specific Cases (in thousand) of Myopia (Children) in the US (2016-2028)
Table 7: Severity Specific Cases (in thousand) of Myopia (Adults) in the US (2016-2028)
Table 8: NVK-002, Clinical Trial Description, 2018
Table 9: United States Market Size of Myopia in USD Million (2016-2028)
Table 10: United States Market Size of Myopia by Therapies in USD Million (2016-2028)
LIST OF FIGURES
Figure 1: Total Prevalent Cases of Myopia in the US (2016-2028)
Figure 2: Age-Specific Cases of Myopia in the US (2016-2028)
Figure 3: Gender Specific Cases of Myopia in the US (2016-2028)
Figure 4: Severity Specific Cases of Myopia (Children) in the US (2016-2028)
Figure 5: Severity Specific Cases of Myopia (Adults) in the US (2016-2028)
Figure 6: Optometric Management of the Patient with Myopia
Figure 7: Unmet Needs for Myopia
Figure 8: United States Market Size of Myopia in USD Million (2016-2028)
Figure 9: United States Market Size of Myopia by Therapies in USD Million (2016-2028)
Figure 10: Market Drivers
Figure 11: Market Barriers
Figure 1: Total Prevalent Cases of Myopia in the US (2016-2028)
Figure 2: Age-Specific Cases of Myopia in the US (2016-2028)
Figure 3: Gender Specific Cases of Myopia in the US (2016-2028)
Figure 4: Severity Specific Cases of Myopia (Children) in the US (2016-2028)
Figure 5: Severity Specific Cases of Myopia (Adults) in the US (2016-2028)
Figure 6: Optometric Management of the Patient with Myopia
Figure 7: Unmet Needs for Myopia
Figure 8: United States Market Size of Myopia in USD Million (2016-2028)
Figure 9: United States Market Size of Myopia by Therapies in USD Million (2016-2028)
Figure 10: Market Drivers
Figure 11: Market Barriers
